Printer Friendly

Browse Antibiotics topic

Product development subtopic

 

Articles

1-125 out of 125 article(s)
Title Author Type Date Words
Bayer and Nektar Pharmaceuticals fail to hit targets in experimental inhaled antibiotic phase III trial. Nov 24, 2017 201
Bayer and Nektar Pharmaceuticals fail to hit targets in experimental inhaled antibiotic phase III trial. Nov 24, 2017 205
FDA and Health Canada Grant Clearance to Appili to Initiate Clinical Trials of Oral Antibiotic. Oct 31, 2017 261
RECCE SUBMITS PRE-IND DATA TO FDA FOR ANTIBIOTIC. Oct 27, 2017 231
Motif Bio plc announces positive topline results from REVIVE-2 trial. Oct 4, 2017 277
Geom Therapeutics to Develop and Commercialize LegoChem Biosciences' Novel Beta Lactamase Inhibitors For Treating Gram-Negative Infections. Sep 27, 2017 808
United Kingdom : Summit announces positive top-line data from an exploratory Phase 2 clinical trial supporting Ridinilazole as a highly selective antibiotic for the treatment of CDI. Sep 12, 2017 700
NIAID, Zavante Partner in Clinical Trial of Zolyd as Bacterial Pneumonia Treatment. Sep 11, 2017 400
PolyPid Ltd. Completes Enrollment in Phase Ib/II Study of D-PLEX(TM) in Post-Cardiac Surgery Sternal Infection. Aug 16, 2017 786
Entasis Therapeutics Partners with CARB-X on Oral, Gram-Negative Programme Development. Mar 31, 2017 392
Debiopharm International reveals positive results from Phase II study of Debio 1450 for ABSSSI. Clinical report Jan 12, 2017 173
Debiopharm International reveals positive results from Phase II study of Debio 1450 for ABSSSI. Clinical report Jan 12, 2017 169
Citius Pharmaceuticals Completes Feasibility Study of Investigator Sites for Mino-Lok(TM) Phase 3 Trials. Jul 18, 2016 859
Symbiomix Therapeutics Announces Positive Results from Phase 3 Trial of SYM-1219 for Bacterial Vaginosis, and Pre-NDA Meeting with FDA Supportive of 2016 NDA Filing. May 26, 2016 1374
BioPharmX Announces Full Patient Enrollment in Phase 2a Study of BPX-01 Topical Antibiotic for Acne. Report Apr 25, 2016 722
Soligenix Announces Publication of Preclinical Efficacy Results with Dusquetide in Infectious Disease. Mar 29, 2016 1952
Synthetic Biologics Initiates SYN-004 Phase 2b Proof-of-Concept Clinical Trial. Sep 28, 2015 1478
Positive Phase III Results Demonstrate Efficacy Of Antibiotic Medicine AVYCAZ(TM) (ceftazidime-avibactam) In Complicated Urinary Tract Infections. Sep 2, 2015 2199
MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections. Clinical report Aug 31, 2015 647
First Participant Dosed in Synthetic Biologics' Second Phase 2a Clinical Trial to Protect the Microbiome and Prevent C. difficile. Jun 12, 2015 1253
Synthetic Biologics' SYN-004 Microbiome-Protecting Preclinical Data Highlighted in Late-Breaking Poster at Digestive Disease Week 2015. May 19, 2015 1146
Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection. Mar 19, 2015 1322
Synthetic Biologics Announces First Patient Dosed in Phase 1a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection. Dec 2, 2014 1308
Ruthigen Announces First Patient Enrollment in the Phase 1/2 Human Clinical Trial of RUT58-60, a Broad-Spectrum Anti-Infective Drug Candidate Designed for Prophylactic Use During Invasive Surgery. Nov 4, 2014 852
Ruthigen Initiates Phase 1/2 Clinical Trial of RUT58-60. Oct 8, 2014 892
Ruthigen Receives Recommendation from Data Monitoring Committee to Initiate Phase 1/2 Human Clinical Trial of RUT58-60. Aug 26, 2014 1187
Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI). Aug 19, 2014 1582
Dipexium Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Locilex in Patients with Mild Infections of Diabetic Foot Ulcers. Jul 17, 2014 1108
Seres Health Completes Enrollment in a Clinical Study for SER-109 in Recurrent Clostridium difficile Infection and Announces Positive Preliminary Data. Jul 16, 2014 772
Belgian Galapagos to start Phase I trial of new antibiotic. Jun 17, 2014 156
United States : AstraZeneca s novel antibiotic candidate AZD0914 given Fast Track status by US FDA. Jun 4, 2014 387
Euprotec, Cantab enter antibiotics development pact. Jun 1, 2014 177
Uncovering new path for drug development. Apr 1, 2014 358
The Medicines Company's MAA for oritavancin for acute bacterial skin and skin structure infections accepted for review by EMA. Feb 28, 2014 213
The Medicines Company's MAA for oritavancin for acute bacterial skin and skin structure infections accepted for review by EMA. Feb 28, 2014 209
Cellceutix Corporation to begin planned Phase 2b clinical trial of novel antibiotic Brilacidin for ABSSSI upon IRB's review. Dec 17, 2013 187
Cellceutix Corporation to begin planned Phase 2b clinical trial of novel antibiotic Brilacidin for ABSSSI upon IRB's review. Dec 17, 2013 183
Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery. Dec 11, 2013 945
Affinium Pharmaceuticals Announces Qualified Infectious Disease Product (QIDP) Designation by the US FDA for AFN-1252 and Completion of Dosing of AFN-1720 Phase 1 Trial. Nov 12, 2013 564
Affinium Pharmaceuticals Announces Qualified Infectious Disease Product (QIDP) Designation by the US FDA for AFN-1252 and Completion of Dosing of AFN-1720 Phase 1 Trial. Nov 12, 2013 559
Otonomy Announces Positive Phase 1b Results for OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery. Financial report Aug 20, 2013 845
Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan. May 13, 2013 1006
Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients. Apr 18, 2013 985
Affinium Pharmaceuticals Announces Positive Efficacy, Safety, and Tolerability Results from Phase 2a Clinical Trial of Oral AFN-1252 in Acute Bacterial Skin & Skin Structure Infections. Mar 21, 2013 950
Affinium Pharmaceuticals Announces Positive Efficacy, Safety, and Tolerability Results from Phase 2a Clinical Trial of Oral AFN-1252 in Acute Bacterial Skin & Skin Structure Infections. Clinical report Mar 20, 2013 985
CrystalGenomics Reports Positive Top-Line Data from Phase 2a Study of CG400549 in Patients with Complicated Acute Bacterial Skin and Skin Structure Infections Caused by MRSA. Clinical report Jan 7, 2013 726
Dipexium Granted Special Protocol Assessment by the FDA for Phase 3 Registration Trial in Mildly Infected Diabetic Foot Ulcers With Locilex(TM). Jan 3, 2013 1408
Dipexium Granted Special Protocol Assessment by the FDA for Phase 3 Registration Trial in Mildly Infected Diabetic Foot Ulcers With Locilex(TM). Jan 3, 2013 1414
Cempra, Inc. Announces Initiation of Oral Solithromycin Global Phase 3 Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia. Clinical report Dec 19, 2012 881
Cempra, Inc. Announces Initiation of CEM-102 Phase 2 Clinical Trial in Patients with Prosthetic Joint Infections. Dec 14, 2012 973
Delphi Genetics Grants Merck License for the Use of the StabyExpress[TM] System. Oct 8, 2012 554
Tetraphase Pharmaceuticals Announces Positive Phase 2 Data for Eravacycline (TP-434) in Patients with Complicated Intra-Abdominal Infections (cIAIs). Sep 12, 2012 832
Affinium Pharmaceuticals, Ltd., Announces Completion of Recruitment for Phase 2 Clinical Trial of AFN-1252 in Acute Bacterial Skin & Skin Structure Infections. Aug 7, 2012 794
Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian Regulator's Approval to Conduct Pivotal Clinical Trial for Sequella's Antibiotic, SQ109, for Tuberculosis. Jul 26, 2012 976
MicuRx Pharmaceuticals Completes Phase 1 Trial For MRX-I, A Next-Generation Antibiotic. Apr 23, 2012 729
Aradigm Receives U.S. FDA Clearance for Phase 3 Clinical Trial of Pulmaquin[TM] in Patients with Non-Cystic Fibrosis Bronchiectasis. Mar 12, 2012 726
Affinium Pharmaceuticals, Ltd., Announces First Patient Dosed With Oral AFN-1252 in a Phase 2 Clinical Trial for Acute Bacterial Skin & Skin Structure Infections. Feb 1, 2012 694
Affinium Pharmaceuticals, Ltd., Announces First Patient Dosed with Oral AFN-1252 in a Phase 2 Clinical Trial for Acute Bacterial Skin & Skin Structure Infections. Feb 1, 2012 676
Basilea reports Phase I data for BAL30072 antibiotic. Sep 19, 2011 244
Basilea commences Phase I study with novel antibiotic BAL30072. Sep 7, 2011 164
Anacor Pharmaceuticals Announces GSK Has Initiated Two Phase 2 Trials of GSK '052 in Complicated Urinary Tract Infections and Complicated Intra-Abdominal Infections. Jun 22, 2011 781
Cubist Announces Positive Results from Two Phase 2 Trials, CXA-201 and CDAD Program. Jun 16, 2011 2286
CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study. Report May 11, 2011 556
Durata Announces Supportive Data Analysis from Phase 3 Dalbavancin Trial at ECCMID Meeting. May 9, 2011 866
PolyMedix Successfully Completes Phase 1 Exposure Escalation Safety Study With PMX-30063 Antibiotic. Feb 24, 2011 1450
Basilea starts Phase I trial of BAL30072 antibiotic. Nov 23, 2010 142
University of Texas Health Science Center Using NanoLogix Technology in 300 Patient Clinical Trial. Oct 19, 2010 1000
Super-antibiotic Research funded. Anderson, Jane Brief article Oct 1, 2010 122
PolyMedix Initiates Phase 2 Clinical Trial with Novel Antibiotic, PMX-30063. Sep 28, 2010 1252
Tetraphase Presents New Clinical and Preclinical Data for Novel AntibioticTP-434 at 2010 ICAAC. Sep 13, 2010 766
Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections. Jul 13, 2010 762
Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use. Jul 8, 2010 1023
Incentives called for to fill antibiotic pipeline. Gingery, Derrick Jul 1, 2010 594
AN3365, A Novel Antibiotic Intended to Treat Infections Caused by Gram-Negative Bacteria, Completes Phase 1 Trial and Achieves Proof of Concept in Collaboration with GSK. Jun 15, 2010 632
Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients. May 17, 2010 1357
CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate. May 10, 2010 446
Cempra Announces Positive Results From its Phase 2 Clinical Trial of TAKSTA(TM) (Sodium Fusidate) in Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Clinical report May 4, 2010 1250
PolyMedix Successfully Completes Phase 1B Clinical Study With Novel Antibiotic PMX-30063. Mar 30, 2010 1352
PolyMedix Successfully Completes Main Portions of Phase 1B Clinical Study with PMX-30063 Novel Antibiotic Drug Candidate. Dec 18, 2009 2064
Anacor Initiates Phase I Clinical Development for AN3365 - A Novel Antibiotic for the Treatment of Gram-Negative Infections. Nov 17, 2009 588
Achaogen Announces ACHN-490 Clinical Data at the 49th Annual ICAAC Meeting. Conference news Sep 14, 2009 803
FAB Pharma, a Biopharma Company Developing Drugs to Treat Severe Bacterial Infections, Raises [euro]2.3 Million in Series A Funding and Begins Recruitment for a Phase I Trial of Its Lead Compound. Sep 12, 2009 431
Cempra Pharmaceuticals Initiates Phase 2/3 Clinical Study for an Oral Antibiotic to Treat Acute Bacterial Skin Structure Infections. Clinical report Sep 9, 2009 506
InSite Vision Announces Clinical Development Plan for ISV-502. Jun 8, 2009 1318
PolyMedix Initiates Dosing in Second Phase I Clinical Study of Novel Systemic Antibiotic Compound. Jun 5, 2009 1295
PolyMedix Receives Regulatory Clearance to Initiate Second Phase I Clinical Study of Novel Systemic Antibiotic Compound. May 21, 2009 1178
Akorn-strides wins O.K. Brief article Feb 2, 2009 251
PolyMedix Announces Positive Phase I Clinical Data with PMX-30063 Novel Antibiotic Drug Candidate. Dec 10, 2008 2177
InSite Vision Announces Preliminary Results From Phase 3 Clinical Trial of ISV-502 for the Treatment of Eyelid Inflammation and Infection. Dec 8, 2008 1451
Targanta Therapeutics Announces Positive Top-Line Results from Oritavancin Phase 2 SIMPLIFI Trial. Financial report Sep 2, 2008 924
PolyMedix Initiates Dosing in Phase I Clinical Study of Novel Systemic Antibiotic Compound. Aug 21, 2008 1186
Post-Patent pendency inclemency: Trailblazing with blindfolds: Examining strategies your company can employ when your patents are pending. Almada, Anthony Jul 1, 2008 834
Targanta's Oritavancin MAA Accepted for Review by EMEA. Jun 25, 2008 877
Targanta Completes Enrollment in Phase 2 Oritavancin Infrequent Dosing Study. May 20, 2008 930
Salix Presents New Rifaximin Phase IIb Data Demonstrating Significant and Sustained Improvement in Diarrhea-Associated Irritable Bowel Syndrome (D-IBS). May 20, 2008 1488
Protez Initiates Phase II Study for Its Lead Product PZ-601 in Infectious Diseases. May 2, 2008 464
Oculus Initiates Patient Enrollment in Phase II Study of Microcyn(R) Technology for Treatment of Mild Diabetic Foot Infections. Clinical report May 21, 2007 837
Oculus Announces Initial Sites for Phase II Clinical Trial of Microcyn(R) Technology in Treatment of Mild Diabetic Foot Infections. Mar 29, 2007 715
REPEAT/FDA Approves New Indication for INVANZ(R) (ertapenem) for the Prevention of Surgical Site Infections (SSI) following Elective Colorectal Surgery in Adults. Dec 21, 2006 12745
FDA Approves New Indication for INVANZ(R) (ertapenem) for the Prevention of Surgical Site Infections (SSI) following Elective Colorectal Surgery in Adults. Dec 20, 2006 12745
Germ zapper. Sohn, Emily Brief article May 24, 2006 318
Amgen expects four drugs to win FDA O.K. Brief Article Dec 19, 2005 242
The potential for developing natural antibiotics: examining oregano and monolaurin. Preuss, Harry G.; Echard, Bobby; Zonosi, Ryan Reza Sep 1, 2005 2843
New class of antibiotics for superbugs. May 1, 2005 367
J&J unveils potential TB breakthrough. Brief Article Jan 1, 2005 278
The FDA:s antibiotic resistance: if bacteria are becoming increasingly resistant to current antibiotics, why is the FDA discouraging the development of new antibiotics? Rubin, Paul H. Dec 22, 2004 2878
Phase III trial: investigative antibiotic treats diabetic infections. MacReady, Norra May 1, 2004 372
Advancis continues to expand patent estate covering antibiotic dosing. Feb 1, 2004 521
Community-acquired pneumonia: help's coming. (New Antibiotics). Boschert, Sherry Dec 1, 2002 535
Daptomycin is equal of oxacillin, vancomycin in skin infections. (Lipopeptide Class). Zoler, Mitchel L. Brief Article Mar 15, 2002 228
Karo Bio and GPC Biotech conclude technology collaboration. Brief Article Feb 6, 2002 124
Genome Therapeutics Sequences Staphylococcus Epidermidis Oct 14, 1997 744
PathoGenesis Initiates Phase II Clinical Trial in Tuberculosis Patients Oct 10, 1997 667
Millennium Pharmaceuticals, Inc. Delivers Three Antibacterial Drug Targets To Wyeth-Ayerst Oct 9, 1997 824
Cubist and Merck Expand Collaboration in Novel Antibiotic Drug Discovery and Development Oct 8, 1997 583
Genome Therapeutics Announces Fourth Milestone in Research Alliance with Schering-Plough to Combat Drug-Resistant Bacteria Oct 2, 1997 431
Study Supports Efficacy of Ciprofloxacin in AECB; Results Demonstrate Superior Bacterial Eradication and Infection-Free Intervals Sep 29, 1997 529
PathoGenesis Updates Investors at Montgomery Conference Sep 25, 1997 470
Dade MicroScan Inc. Receives FDA Approval for New Strep Testing Procedure. Dec 26, 1996 247
GALAGEN ANNOUNCES PROMISING PHASE I/II CLINICAL RESULTS FOR SPORIDIN-G IN THE JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROME AND HUMAN RETROVIROLOGY. Dec 2, 1996 883
AKORN RECEIVES SIGNIFICANT ANTIBIOTIC AND FOURTH GENERIC APPROVAL FOR ITS DECATUR, ILLINOIS FACILITY Feb 7, 1996 351
ALAMAR BIOSCIENCES ADDS MAJOR ANTIBIOTIC TO DIAGNOSTIC TEST KITS AFTER SECURING FDA CLEARANCE Jul 15, 1993 293
PHASE I CLINICAL TRIALS OF MIKASOME INITIATED BY VESTAR; LIPOSOMAL FORMULATION OF ANTIBIOTIC MAY COMBAT RESISTANT TB Jul 7, 1993 304
MAGAININS -- NEW CLASS OF ANTIBIOTICS -- SLATED FOR HUMAN TESTING AND CANCER RESEARCH Jun 11, 1992 267
BELMAC REPORTS PROGRESS ON BIOLID(TM) IN FRANCE Mar 18, 1992 344

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters